Study Designs and statistical analyses for biomarker research

Sensors (Switzerland)

Volumn 12, Issue 7, 2012, Pages 8966-8986

  Gosho, Masahiko ^a   Nagashima, Kengo ^a,b   Sato, Yasunori ^c  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b JOSAI UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker adaptive design; Confounding; Multiplicity; Predictive factor; Statistical test

Indexed keywords

BIOLOGICAL MARKER;

HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN;

EID: 84864330096     PISSN: 14248220     EISSN: None     Source Type: Journal    
DOI: 10.3390/s120708966     Document Type: Review

References (64)

1. Ioannidis, J.P.; Panagiotou, O.A. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. J. Am. Med. Assoc. 2011, 305, 2200-2210.
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89-95.
3. Frank, R.; Hargreaves, R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2003, 2, 566-580.
4. Hayes, D.F.; Bast, R.C.; Desch, C.E.; Daniel, F.; Fritsche, H.; Kemeny, N.E.; Jessup, J.M.; Locker, G.Y.; Macdonald, J.S.; Mennel, R.G.; et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 1996, 88, 1456-1466.
5. Jenkins, M.; Flynn, A.; Smart, T.; Harbron, C.; Sabin, T.; Ratnayake, J.; Delmar, P.; Herath, A.; Jarvis, P.; Matcham, J.; On behalf of the PSI Biomarker Special Interest Group. A statistician's perspective on biomarkers in drug development. Pharm. Stat. 2011, 6, 494-507.
6. Ludwig, J.A.; Weinstein, J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5, 845-856.
7. Mega, J.L.; Close, S.L.; Wiviott, S.D.; Shen, L.; Hockett, R.D.; Brandt, J.T.; Walker, J.R.; Antman, E.M.; Macias, W.; Braunwald, E.; Sabatine, M.S. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009, 360, 354-362.
8. Simon, R. The use of genomics in clinical trial design. Clin. Cancer Res. 2008, 14, 5984-5993.
9. Wang, Z.Y.; Chen, Z. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 2008, 1, 2505-2515.
10. Berger, R.; Huelsman, M.; Strecker, K.; Bojic, A.; Moser, P.; Stanek, B.; Pacher, R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002, 21, 2392-2397.
11. Buyse, M.; Michiels, S.; Sargent, D.J.; Grothey, A.; Mateson, A.; de Gramont, A. Integrating biomarkers in clinical trials. Expert Rev. Mol. Diagn. 2011, 11, 171-182.
12. Hayes, D.F.; Trock, B.; Harris, A.L. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? Breast. Cancer. Res. Treat. 1998, 52, 305-319.
13. Simon, R.; Altman, D.G. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer 1994, 69, 979-985.
14. Sargent, D.J.; Conley, B.A.; Allegra, C.; Collette, L Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 2005, 23, 2020-2027.
15. Chakravarty, A.G.; Rothmann, M.; Sridhara, R. Regulatory issues in use of biomarkers in oncology trials. Stat. Biopharm. Res. 2011, 3, 569-576.
16. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, H.; Shimokata, K.; Hasegawa, Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res. 2000, 60, 6921-6926.
17. Innocenti, F.; Undevia, S.D.; Iyer, L.; Chen, P.X.; Das, S.; Kocherginsky, M.; Karrison, T.; Janisch, L.; Ramírez, J.; Rubin, C.M.; et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 2004, 22, 1382-1388.
18. Marcuello, E.; Altés, A.; Menoyo, A.; Del Rio, E.; Gómez-Pardo, M.; Baiget, M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 2004, 91, 678-682.
19. Rouits, E.; Boisdron-Celle, M.; Dumont, A.; Guerin, O.; Morel, A.; Gamelin, E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin. Cancer Res. 2004, 10, 5151-5159.
20. Ellenberg, S.S.; Hamilton, J.M. Surrogate endpoints in clinical trials: Cancer. Stat. Med. 1989, 8, 405-413.
21. Prentice, R.L. Surrogate endpoints in clinical trials: Definitions and operational criteria. Stat. Med. 1989, 8, 431-440.
22. Fleming, T.R.; DeMets, D.L. Surrogate end points in clinical trials: Are we being misled? Ann. Intern. Med. 1996, 125, 605-613.
23. Mandrekar, S.J.; Sargent, D.J. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J. Clin. Oncol. 2009, 27, 4027-4034.
24. Mandrekar, S.J.; Sargent, D.J. Clinical trial designs for predictive biomarker validation: One size does not fit all. J. Biopharm. Stat. 2009, 19, 530-542.
25. Clinical Trials (PDQ®) National Cancer Institute. Available online: http://www.cancer.gov/clinicaltrials/CALGB-30506 (accessed on 31 May 2012).
26. Potti, A.; Mukherjee, S.; Petersen, R.; Dressman, H.K.; Bild, A.; Koontz, J.; Kratzke, R.; Watson, M.A.; Kelley, M.; Ginsburg, G.S.; et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 570-580.
27. Freidlin, B.; McShane, L.M.; Korn, E.L. Randomized clinical trials with biomarkers: Design issues. J. Natl. Cancer Inst. 2010, 102, 152-160.
28. Hoering, A.; LeBlanc, M.; Crowley, J.J. Randomized Phase III clinical trial designs for targeted agents. Clin. Cancer Res. 2008, 14, 4358-4367.
29. Lee, J.J.; Gu, X.; Liu, S. Bayesian adaptive randomization designs for targeted agent development. Clin. Trials 2010, 7, 584-596.
30. Young, K.Y.; Laird, A.; Zhou, X.H. The efficiency of clinical trial designs for predictive biomarker validation. Clin. Trials 2010, 7, 557-566.
31. Clinicaltrials. gov: NCT00174629. GILT docetaxel-non-small cell lung cancer. Available online: http://clinicaltrials.gov/ct2/results?term=NCT00174629 (accessed on 13 March 2012).
32. Cobo, M.; Isla, D.; Massuti, B.; Montes, A.; Sanchez, J.M.; Provencio, M.; Viñolas, N.; Paz-Ares, L.; Lopez-Vivanco, G.; Muñoz, M.A.; et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A Phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25, 2747-2754.
33. Simon, R.; Maitournam, A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res. 2004, 10, 6759-6763.
34. Chow, S.C.; Liu, J.P. Designs for Clinical Trials. Designs for Clinical Trials. In Design and Analysis of Clinical Trials, 2nd ed.; Wiley & Sons: New York, NY, USA, 2004; pp. 194-214.
35. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783-792.
36. Piccart-Gebhart, M.J.; Procter, M.; Leyland-Jones, B.; Goldhirsch, A.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Bell, R.; Jackisch, C.; et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1659-1672.
37. Cronin, M.; Sangli, C.; Liu, M.L.; Pho, M.; Dutta, D.; Nguyen, A.; Jeong, J.; Wu, J.; Langone, K.C.; Watson, D. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptorpositive breast cancer. Clin. Chem. 2007, 53, 1084-1091.
38. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.L.; Walker, M.G.; Watson, D.; Park, T.; et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351, 2817-2826.
39. Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim, W.; Cronin, M.; Baehner, F.L.; Watson, D.; Bryant, J.; et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J. Clin. Oncol. 2006, 24, 3726-3734.
40. Sparano, J.A.; Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 2008, 26, 721-728.
41. Zujewski, J.A.; Kamin, L. Trial assessing individualized options for treatment for breast cancer: The TAILORx trial. Future Oncol. 2008, 4, 603-610.
42. Freidlin, B.; Simon, R. Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin. Cancer Res. 2005, 11, 7872-7878.
43. Freidlin, B.; Jiang, W.; Simon, R. The cross-validated adaptive signature design. Clin. Cancer Res. 2010, 16, 691-698.
44. Jiang, W.; Freidlin, B.; Simon, R. Biomarker adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. J. Natl. Cancer Inst. 2007, 99, 1036-1043.
45. Wang, S.J.; O'Neill, R.T.; Hung, H.M.J. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm. Stat. 2007, 6, 227-244.
46. Zhou, X.; Liu, S.; Kim, E.S.; Herbst, R.S.; Lee, J.J. Bayesian adaptive design for targeted therapy development in lung cancer: A step towards personalized medicine. Clin. Trials 2008, 5, 181-193.
47. Albert, J.H.; Chib, S. Bayesian analysis of binary and polychotomous response Data. J. Am. Stat. Assoc. 1993, 88, 669-679.
48. Food and Drug Administration. Guidance for industry and FDA staff: Guidance for the use of bayesian statistics in medical device clinical trials. Available online: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071121.pdf (accessed on 31 May 2012).
49. Korn, E.L.; Midthune, D.; Chen, T.T.; Rubinstein, L.V.; Christian, M.C.; Simon, R.M. A comparison of two phase I trial designs. Stat. Med. 1994, 13, 1799-1806.
50. Chow, S.C. Encyclopedia of Biopharmaceutical Statistics; Marcel Dekker: New York, NY, USA, 2000; p. 245.
51. Lagakos, S.W. The challenge of subgroup analyses-Reporting without distorting. N. Engl. J. Med. 2006, 354, 1667-1669.
52. Cox, D.R. Regression models and life-tables. J. Roy. Stat. Soc. B. Met. 1972, 34, 187-220.
53. Assmann, S.F.; Pocock, S.J.; Enos, L.E.; Kasten, L.E. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000, 355, 1064-1069.
54. Chen, J.J.; Roberson, P.K.; Schell, M.J. The false discovery rate: A key concept in large-scale genetic studies. Cancer Control 2010, 17, 58-62.
55. Lehmann, E.L.; Romano, J.P. Testing Statistical Hypotheses, 3rd ed.; Springer-Verlag: New York, NY, USA, 2005.
56. Feise, R.J. Do multiple outcome measures require p-value adjustment? BMC Med. Res. Methodol. 2002, 2, 8.
57. Bauer, P. Multiple testing in clinical trials. Stat. Med. 1991, 10, 871-890.
58. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B 1995, 57, 289-300.
59. Westfall, P.H.; Young, S.S. Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment; Wiley & Sons: New York, NY, USA, 1993.
60. Godfrey, K.A.M. Comparing the means of several groups. N. Engl. J. Med. 1985, 313, 1450-1456.
61. Hochberg, Y.; Tamhane, A.C. Multiple Comparison Procedures. Wiley & Sons: New York, NY, USA, 1987.
62. Miller, R.G. Simultaneous Statistical Inference, 2nd ed.; Springer-Verlag: New York, NY, USA, 1981.
63. Tamhane, A.C. Multiple Comparisons. In Handbook of Statistics; Gosh S., Rao, C.R., Eds.; Elsevier Science Publishing Company: North-Holland, The Netherlands, 1996; Volume 13, pp. 587-630.
64. ICH E9 Expert Working Group. Statistical principles for clinical trials: ICH harmonized tripartite guideline. Stat. Med. 1999, 18, 1905-1942.